Psoriatic arthritis

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

Retrieved on: 
Donnerstag, Mai 9, 2024
Psoriatic arthritis, Hyperglycemia, Graves' ophthalmopathy, Abscess, Huber loss, Risk, QW, Hidradenitis suppurativa, Conference, Webcast, Suicidal ideation, Development, MRCP, Disease, Patient, Fungus, LOS, SLRN, Diplopia, FRCP, IL-17A, POC, CAS, Quality of life, Exophthalmos, Behavior, Infection, Pharmaceutical industry

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today provided an update on various corporate milestones.

Key Points: 
  • This Phase 2b/3 trial, designed to be the first of two registrational trials in TED, is planned to be initiated in the second half of 2024.
  • Izokibep in Uveitis (UV): ACELYRIN expects to complete enrollment in the ongoing Phase 2b/3 trial this month and top line data are anticipated by year-end 2024.
  • ACELYRIN expects to report cash, cash equivalents, and short-term marketable securities of $678.5 million at March 31, 2024.
  • Gil Labrucherie, who serves as ACELYRIN’s Chief Financial Officer, has also been named Chief Business Officer in addition to Chief Financial Officer.

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
Dienstag, Mai 7, 2024
Komodo, Psoriatic arthritis, VELA, FDA, American Academy, Porokeratosis, Psoriasis, HS, Skin, Rheumatology, MDA, Research, Partnership, Conference, PPP, MIRA, Joint, Bimekizumab, Patient, EMA, AAD, Inflammation, PASI, Moonlake, Dermatology, ARGO, Pharmaceutical industry

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.
  • Research and development expenses for the quarter ended March 31, 2024, were $13.0 million, compared to $8.1 million in the previous quarter.
  • The increase was primarily due to expenses incurred to initiate the new clinical trials.
  • General and administrative expenses for the quarter ended March 31, 2024 were $6.8 million, similar to the $6.9 million incurred in the previous quarter.

Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Retrieved on: 
Dienstag, April 16, 2024
Psoriatic arthritis, Launch, HCP, Rheumatology, Patient, Need for Speed, Benchmarking, MOA, RealTime, IL-17A, Growth, Overalls, Ankylosing spondylitis, Pharmaceutical industry

Approximately five months post-approval, over one-third of US rheumatologists (n=104) report prescribing the IV formulation for their patients with PsA.

Key Points: 
  • Approximately five months post-approval, over one-third of US rheumatologists (n=104) report prescribing the IV formulation for their patients with PsA.
  • Furthermore, the vast majority feel the new formulation of Novartis’ IL-17-inhibitor brings some degree of advance over existing PsA treatments.
  • Receptivity to the IV formulation has also resulted in a greater affinity for the Cosentyx brand overall, specifically in comparison to long-standing IL-17 rival, Eli Lilly’s Taltz.
  • Launch tracking of Bimzelx will commence following approval and will continue for the first eighteen months of availability through the Launch Dynamix™ service.

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Retrieved on: 
Dienstag, April 16, 2024
Volunteering, FDA, Psoriatic arthritis, Safety, Food, Cytokine, Johnson & Johnson, Teva, TEVA, Inflammation, Partnership, Perfusion, Biotechnology, Senior, Patient, Psoriasis, Marketing, PASI, Teva Pharmaceuticals, Generic drug

Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.

Key Points: 
  • Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.
  • Alvotech handles development and manufacturing, while Teva is responsible for the exclusive commercialization in the U.S., which leverages Teva’s experience and extensive sales and marketing infrastructure.
  • SELARSDI is the second biosimilar approved under the strategic partnership: in February 2024, the FDA approved SIMLANDI®, the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA.
  • The FDA approval of SELARSDI, referred to as AVT04 during development, was based on a totality of evidence, including analytical and clinical data.

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 

Retrieved on: 
Mittwoch, April 10, 2024
Komodo, Psoriatic arthritis, Arthropathy, Holocene, HS, Skin, Hidradenitis suppurativa, Partnership, Research, Literature, Entrepreneurship, Disease, Steroid, Patient, Inflammation, Marketing, Moonlake, Prevalence, Pharmaceutical industry

San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams.
  • Komodo’s data and technology applications will support MoonLake’s in-depth market research, clinical trial site selection, go-to-market strategies, and patient journey mapping – all aimed at accelerating the development of new treatment options and improving outcomes for patients with inflammatory skin and joint diseases.
  • Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Retrieved on: 
Dienstag, April 16, 2024
Biotechnology, Pharmaceutical, Oncology, Health, FDA, Health Technology, Genetics, Clinical Trials, Volunteering, Psoriatic arthritis, Safety, Food, Cytokine, Johnson & Johnson, Teva, TEVA, Inflammation, Partnership, Perfusion, Senior, Patient, Psoriasis, Multimedia, Marketing, PASI, Teva Pharmaceuticals, Generic drug

Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.

Key Points: 
  • Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.
  • Alvotech handles development and manufacturing, while Teva is responsible for the exclusive commercialization in the U.S., which leverages Teva’s experience and extensive sales and marketing infrastructure.
  • SELARSDI is the second biosimilar approved under the strategic partnership: in February 2024, the FDA approved SIMLANDI®, the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA.
  • The FDA approval of SELARSDI, referred to as AVT04 during development, was based on a totality of evidence, including analytical and clinical data.

Popular ArthritisPower® Patient Registry Expands Conditions and Becomes PatientSpot™

Retrieved on: 
Montag, April 15, 2024
Technology, FDA, Managed Care, Health, General Health, Health Technology, Medical Devices, Research, Apps, Applications, Artificial Intelligence, Science, Conditional sentence, Education, University, Patient, Psoriatic arthritis, Food, Spondyloarthropathy, Partnership, Human, Habit, Intelligence, Entrepreneurship, Arthritis, MPH, Rheumatoid arthritis, Medicine, UAB, Movement, RMD, Nursing

Patients can now join the registry and its community with any chronic condition they wish to share, establishing it as a truly disease-agnostic platform.

Key Points: 
  • Patients can now join the registry and its community with any chronic condition they wish to share, establishing it as a truly disease-agnostic platform.
  • Erik Stone, MA, Associate Director, Learning Experience Design at GHLF, explained, “Many of the patients we assist navigate multiple chronic conditions alongside arthritis.
  • It emerged as an innovative nationwide research registry, focusing on patients with rheumatic and musculoskeletal conditions (RMD), including rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis.
  • “We treasure the insights and experiences shared by patients dealing with arthritis and related conditions.

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Retrieved on: 
Mittwoch, April 10, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Artificial Intelligence, Other Science, Other Technology, Research, Software, General Health, Health Technology, Science, Data Management, Komodo, Psoriatic arthritis, Arthropathy, Holocene, HS, Skin, Hidradenitis suppurativa, Marketing, Partnership, Literature, Entrepreneurship, Disease, Steroid, Patient, Inflammation, Multimedia, Moonlake, Prevalence, Pharmaceutical industry

MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • View the full release here: https://www.businesswire.com/news/home/20240410438883/en/
    Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision-making across its clinical operations, medical, marketing, and market access teams.
  • Tino Anthamatten, VP, Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.
  • The real-world insights from Komodo helped validate a future HS market size projected to exceed $10B by 2035.

Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease

Retrieved on: 
Donnerstag, April 11, 2024
Pain, Itch, Psoriatic arthritis, Rheumatology, Conference, Research, Science, Mental health, Antimicrobial spectrum, Diagnosis, Dermatology, Knowledge, Nursing

This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."

Key Points: 
  • This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."
  • We are honored to have April Armstrong, Chair of the Scientific Executive Committee (SEC), as the President of the 7th IFPA Conference.
  • By attending workshops, seminars, and keynote presentations, participants can enhance their knowledge and skills in various aspects of psoriatic disease.
  • Engage with leading experts, participate in insightful discussions, and contribute to shaping the future of psoriatic disease research and advocacy.

Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease

Retrieved on: 
Donnerstag, April 11, 2024
Pain, Itch, Psoriatic arthritis, Rheumatology, Conference, Research, Science, Mental health, Antimicrobial spectrum, Diagnosis, Dermatology, Knowledge, Nursing

This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."

Key Points: 
  • This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."
  • We are honored to have April Armstrong, Chair of the Scientific Executive Committee (SEC), as the President of the 7th IFPA Conference.
  • By attending workshops, seminars, and keynote presentations, participants can enhance their knowledge and skills in various aspects of psoriatic disease.
  • Engage with leading experts, participate in insightful discussions, and contribute to shaping the future of psoriatic disease research and advocacy.